Design Therapeutics, Inc.

DSGN Nasdaq SEC CIK 1807120
Follow Design Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$20.3M −19.4% vs same quarter last year
EPS, diluted −$0.32 −6.7% vs same quarter last year
Operating cash flow −$15.4M −37.8% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
$0
$0
$0
Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$80M−$60M−$40M−$20M$0$20MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$0−$69.8M
FY24$0−$49.6M
FY23-−$66.9M
FY22-−$63.3M
FY21-−$35.5M
FY20$226K−$8.3M
FY19--
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$54.6M
FY24−$43.4M
FY23−$58.8M
FY22−$52.2M
FY21−$30.9M
FY20−$8.7M
FY19-